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Congenital heart disease, exercise capacity
and B-type natriuretic peptide
The study by Trojnarska et al. [1] is very in-
teresting and adds important information to what
we know about adults with congenital heart disease
and heart failure.
Heart failure can be considered as an advanced
stage of heart disease, and is a significant cause of
worldwide mortality and morbidity [2]. It is charac-
terized by a persistent activation of the circadian
neurohormonal system [3, 4], endothelial dysfunc-
tion [5], exercise intolerance [6–9], high mortality [10]
and an impaired quality of life [11].
Trojnarska et al. [1] studied 265 adult patients
with congenital heart disease and found that the ex-
ercise capacity of this population was compromised;
despite the fact that 78% of the studied patients self-
-assessed their exercise capacity as satisfactory.
Moreover, the B-type natriuretic peptide (BNP)
levels were increased and closely correlated with
exercise capacity.
Surprisingly, in a sub-analysis, the authors
found that lower peak oxygen consumption was
observed in patients with corrected tetralogy of
Fallot and higher BNP concentration in Ebstein’s
anomaly. It is well known that peak oxygen con-
sumption [10] and BNP [12] can stratify the heart
failure patient’s severity. Regarding this sub-ana-
lysis, one would expect that the tetralogy of Fallot
would have higher BNP concentrations, and
Ebstein’s  anomaly the lowest peak oxygen consump-
tion. It would be interesting if a correlation between
peak oxygen consumption and BNP concentration
could have been performed to each kind of congen-
ital heart disease.
The study by Trojnarska et al. [1] leads us to
conclude that heart failure in adults with congeni-
tal heart disease is under-diagnosed and special at-
tention must be provided from clinicians to these
patients to avoid growing numbers succumbing to
this syndrome.
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